Currently, demethylating agents and HDAC inhibitors are being studied as adjuvant treatment options for NSCLC and other human malignancies, and combinations of these drugs continue to undergo bench-top and clinical investigation [39], [40], [41]. This evidence concerns the gene HDAC9 and non-small cell lung carcinoma.